RUNX1 participation in chemotherapy drug response has also been reported in ovarian cancer [60], glioblastoma multiforme [61] and colorectal cancer [62], suggesting that this function could be a general molecular mechanism of action that favors tumor aggressiveness against cytostatic drug treatment. Here, RUNX1 is linked to neoplasm.